N. Masuda

T. Shien, M. Ishitobi, T. Taguchi, 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.

M. Robson, Bing-he Xu, N. Tung, 2019, European journal of cancer.

Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study

H. Iwata, N. Masuda, S. Morita, 2017, Breast Cancer.

Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: a multi-institution survey

N. Masuda, S. Morita, M. Toi, 2009, Breast Cancer Research and Treatment.

Study of Low-Dose Capecitabine Monotherapy for Metastatic Breast Cancer

J. Sakamoto, T. Taguchi, S. Noguchi, 2010, Chemotherapy.

Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031)

N. Masuda, N. Niikura, N. Hayashi, 2022, Japanese journal of clinical oncology.

High expression of two genes selected by iAFLP: a new prognostic factor of estrogen receptor-positive breast cancer.

M. Monden, Y. Tamaki, S. Noguchi, 2004, Oncology reports.

Adjuvant Capecitabine for Breast Cancer.

Y. Ohashi, N. Masuda, M. Toi, 2017, The New England journal of medicine.

First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial

N. Masuda, Masato Takahashi, M. Kashiwaba, 2017, Japanese journal of clinical oncology.

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.

D. Miles, D. Cameron, J. Canon, 2017, European journal of cancer.

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.

S. Loi, D. Cescon, V. Karantza, 2022, The New England journal of medicine.

Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR

H. Sasano, N. Masuda, M. Toi, 2019, International journal of molecular sciences.

Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004–2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society

H. Miyata, Masayuki Yoshida, T. Kinoshita, 2019, Breast Cancer.

Rechallenge of anti-PD-1/PD-L1 antibody showed a good response to metastatic breast cancer: a case report.

K. Mori, N. Masuda, M. Mano, 2020, Immunotherapy.

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)

N. Taira, F. Hara, H. Iwata, 2022, Cancer science.

A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy.

M. Shibuya, N. Masuda, K. Kubota, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).

M. Robson, Bing-he Xu, N. Tung, 2017 .

Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy

Y. Ohashi, K. Suemasu, N. Masuda, 2011, Oncology.

Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm

H. Iwata, M. Sugimoto, N. Masuda, 2018, Breast Cancer Research and Treatment.

Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients

H. Iwata, Tsuyoshi Saito, N. Masuda, 2015, International Journal of Clinical Oncology.

Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer.

N. Masuda, K. Kubota, M. Takada, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolomus, new target drug for mTOR in the field of breast cancer treatment

N. Masuda, 2015 .

Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study

H. Iwata, H. Mukai, Y. Ohashi, 2017, Cancer.

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study

H. Iwata, Kenichi Inoue, N. Masuda, 2020, Cancer medicine.

Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan

S. Takashima, J. Watanabe, J. Horiguchi, 2013, Cancer Chemotherapy and Pharmacology.

Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer

E. Tokunaga, H. Iwata, A. Shimomura, 2020, Breast Cancer Research and Treatment.

Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG

H. Iwata, H. Tsuda, F. Akiyama, 2015, Breast Cancer.

Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results from a phase I/II trial.

H. Iwata, K. Yonemori, N. Masuda, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Preliminary result of accelerated partial breast irradiation after breast-conserving surgery

T. Nose, H. Yamazaki, N. Masuda, 2009, Breast cancer.

MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer

P. Neven, G. Sledge, S. Johnston, 2021, Clinical Cancer Research.

Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2.

J. Baselga, H. Rugo, M. Campone, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

N. Masuda, Seigo Nakamura, Y. Rai, 2015, Supportive Care in Cancer.

Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.

N. Taira, H. Iwata, N. Masuda, 2022, The Lancet. Oncology.

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.

N. Taira, F. Hara, H. Iwata, 2018, Japanese journal of clinical oncology.

A prospective analysis of two studies that used the 5-mm interval slices and 5-mm margin-free method for ipsilateral breast tumor recurrence after breast-conserving surgery without radiotherapy

E. Tokunaga, Y. Ohashi, K. Suemasu, 2022, Breast Cancer.

Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.

T. Mukohara, M. Ono, T. Shimoi, 2022, European journal of cancer.

A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)

E. Tokunaga, N. Kondo, N. Masuda, 2021, Breast Cancer Research and Treatment.

Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)

N. Masuda, S. Morita, S. Ohtani, 2021, International Journal of Clinical Oncology.

Objective and longitudinal assessment of dermatitis after postoperative accelerated partial breast irradiation using high-dose-rate interstitial brachytherapy in patients with breast cancer treated with breast conserving therapy: reduction of moisture deterioration by APBI.

Y. Yoshioka, H. Yamazaki, E. Tanaka, 2011, International journal of radiation oncology, biology, physics.

Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial

N. Masuda, Seigo Nakamura, Y. Tokuda, 2015, Supportive Care in Cancer.

Breast cancer in young women : Issues and perspectives regarding patients ’ and survivors ’ care Clinicopathological features of young patients ( < 35 years of age ) with breast cancer in a Japanese Breast Cancer Society supported study

T. Shien, E. Tokunaga, N. Masuda, 2014 .

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication

H. Iwata, H. Sasano, N. Masuda, 2019, ESMO Open.

CODE chemotherapy with or without recombinant human granulocyte colony-stimulating factor in extensive-stage small cell lung cancer.

M. Fukuoka, N. Masuda, K. Furuse, 1992, Oncology.

Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study

H. Iwata, K. Yonemori, N. Masuda, 2022, Breast Cancer.

Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer

J. Watanabe, N. Masuda, Y. Koibuchi, 2022, International journal of nanomedicine.

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer

A. Schneeweiss, M. Parmar, J. Mackey, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD

M. Robson, Bing-he Xu, N. Tung, 2018 .

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies

H. Rugo, R. Finn, N. Masuda, 2020, Breast Cancer Research.

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.

H. Iwata, Masayuki Yoshida, H. Mukai, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer

Kenichi Inoue, N. Masuda, S. Morita, 2020, Breast Cancer Research and Treatment.

Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.

Sung-Bae Kim, H. Iwata, Bing-he Xu, 2019, Future oncology.

Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: A multi-institution survey.

N. Masuda, S. Morita, M. Toi, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.

E. Tokunaga, H. Iwata, K. Yonemori, 2022, Japanese journal of clinical oncology.

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

Sung-Bae Kim, H. Iwata, Byeong‐Woo Park, 2017, The New England journal of medicine.

Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2

Y. C. Heng, M. Piccart, G. Hortobagyi, 2013, Breast Cancer Research and Treatment.

Clinical significance of evaluating hormone receptor and HER2 protein using cell block against metastatic breast cancer: a multi-institutional study

E. Tokunaga, K. Mori, S. Ichihara, 2019, Oncotarget.

Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer.

M. Fukuoka, N. Masuda, S. Kudoh, 1991, Journal of the National Cancer Institute.

PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib Plus Fulvestrant in Postmenopausal Women With Endocrine-resistant HR+/HER2- Advanced Breast Cancer: First Results From the Randomized, Phase III BELLE-2 Trial

J. Baselga, H. Iwata, W. Jonat, 2015 .

Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.

M. Fukuoka, N. Masuda, S. Kudoh, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Prognosis of small cell lung cancer with ipsilateral pleural effusion].

N. Masuda, S. Kudoh, M. Takada, 1992, Nihon Kyobu Shikkan Gakkai zasshi.

Detection of microsatellite alterations in nipple discharge accompanied by breast cancer

N. Tomita, M. Monden, Y. Tamaki, 2000, Breast Cancer Research and Treatment.

Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria

H. Katayama, N. Masuda, A. Yokomizo, 2015, Surgery Today.

Primary Chest Wall Abscess Mimicking a Breast Tumor That Occurred after Blunt Chest Trauma: A Case Report

N. Masuda, M. Sekimoto, K. Kuriyama, 2014, Case reports in medicine.

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

C. Isaacs, Bing-he Xu, F. André, 2014, The Lancet. Oncology.

Primary signet-ring cell carcinoma of the colon and rectum: report of eight cases and review of 154 Japanese cases.

N. Masuda, T. Tsujinaka, M. Takeda, 2006, Hepato-gastroenterology.

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

A. Garg, M. Piccart, G. Hortobagyi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases.

M. Robson, Bing-he Xu, N. Tung, 2018 .

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

M. Robson, Bing-he Xu, N. Tung, 2017, The New England journal of medicine.

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

M. Buyse, N. Robert, M. Gnant, 2016, The Lancet. Oncology.

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Norikazu Masuda, Stephen Chia, Mark Clemons, 2017, The Lancet. Oncology.

Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples

Norikazu Masuda, Tsutomu Iwasa, Takayuki Iwamoto, 2019, Scientific Reports.

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

P. Neven, G. Sledge, S. Johnston, 2019, JAMA oncology.

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

P. Neven, G. Sledge, X. Pivot, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3.

S. Loi, H. Rugo, H. Iwata, 2021 .

Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.

S. Loi, A. DeMichele, Xin Huang, 2018, European journal of cancer.

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3

H. Rugo, M. Goetz, J. Huober, 2020, The oncologist.

The Challenge to Overcome Triple-Negative Breast Cancer Heterogeneity

N. Masuda, H. Masuda, 2016 .

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

S. Loi, D. Cescon, V. Karantza, 2020 .

Breast Cancer Subtype and Distant Recurrence after Ipsilateral Breast Tumor Recurrence

T. Shien, M. Ishitobi, T. Taguchi, 2013, Annals of Surgical Oncology.

The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy.

F. Akiyama, S. Masuda, S. Noguchi, 2014, Cancer letters.

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy

Teruhiko Yoshida, Masayuki Yoshida, A. Shimomura, 2019, Translational oncology.

A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.

Teruhiko Yoshida, A. Shimomura, K. Yonemori, 2019, European journal of cancer.

Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.

G. Hortobagyi, J. Baselga, H. Rugo, 2013 .

A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.

M. Fukuoka, N. Masuda, S. Kudoh, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens

P. Ang, K. Rau, M. Hou, 2021, Breast Cancer Research and Treatment.

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer

N. Masuda, N. Masuda, S. Morita, 2014, Cancer Chemotherapy and Pharmacology.

Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression

H. Iwata, Y. Fujiwara, Kenichi Inoue, 2014, Breast Cancer Research and Treatment.

Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels

N. Masuda, M. Toi, T. Kawaguchi, 2022, Cancer management and research.

Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer.

M. Fukuoka, N. Masuda, S. Kudoh, 1991, Journal of the National Cancer Institute.

Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.

E. Tokunaga, M. Kurosumi, Y. Miyoshi, 2008, Cancer letters.

Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer

H. Iwata, A. Shimomura, K. Tamura, 2021, BMC Cancer.

Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214

M. Yamaguchi, N. Masuda, S. Morita, 2021, Cancers.

Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study)

M. Okada, N. Masuda, S. Ohno, 2021, Breast Cancer.

Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy

G. Sledge, H. Iwata, H. Mukai, 2021, Breast Cancer.

Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study)

N. Masuda, S. Morita, M. Toi, 2020, Investigational New Drugs.

Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (

N. Masuda, Masato Takahashi, S. Morita, 2020, Trials.

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERA

N. Masuda, Masato Takahashi, S. Morita, 2020, Trials.

A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer

N. Masuda, Masato Takahashi, S. Tanaka-Mizuno, 2020, Breast Cancer Research and Treatment.

Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study

N. Masuda, Masato Takahashi, S. Morita, 2019, Japanese journal of clinical oncology.

Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study

Sung-Bae Kim, C. Shimizu, H. Mukai, 2019, Journal of global oncology.

Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast Cancer

N. Shinkura, T. Kinoshita, T. Taguchi, 2015, Annals of Surgical Oncology.

[Anomalous systemic arterial supply to the basal segment of the left lung; report of a case].

H. Imamura, N. Masuda, H. Furukawa, 2003, Kyobu geka. The Japanese journal of thoracic surgery.

Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.

M. Dowsett, S. Loi, H. Iwata, 2017, The oncologist.

Tumor thickness and histological features as predictors of invasive foci within preoperatively diagnosed ductal carcinoma in situ.

K. Mori, Y. Kodama, N. Masuda, 2017, Human pathology.

Abstract PD4-03: OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

M. Robson, Bing-he Xu, N. Tung, 2020 .

Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study

N. Taira, H. Iwata, Y. Ohashi, 2018, Breast Cancer Research and Treatment.

Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer

T. Yamanaka, H. Iwata, H. Sasano, 2013, International Journal of Clinical Oncology.

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.

H. Iwata, T. Kinoshita, S. Noguchi, 2012, The Lancet. Oncology.

Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition

H. Iwata, Takashi Suzuki, H. Sasano, 2011, Cancer science.

Predictive factors for anthracycline-based chemotherapy for human breast cancer

E. Tokunaga, M. Kurosumi, Y. Miyoshi, 2010, Breast cancer.

Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers

E. Tokunaga, M. Kurosumi, Y. Miyoshi, 2008, Journal of Cancer Research and Clinical Oncology.

Clinical significance of micrometastases in axillary lymph nodes assessed by reverse transcription-polymerase chain reaction in breast cancer patients.

M. Monden, Y. Tamaki, N. Masuda, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer

S. Kudoh, T. Yamanaka, M. Fukuoka, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

S. Loi, H. Rugo, H. Iwata, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.

C. Shimizu, Y. Fujiwara, H. Tsuda, 2009, Japanese journal of clinical oncology.

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

K. Eguchi, Y. Fujiwara, Y. Ohashi, 2009, Breast Cancer Research and Treatment.

Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer

H. Iwata, N. Masuda, Ken-ichi Watanabe, 2017, Oncotarget.

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial

T. Yamanaka, H. Iwata, H. Sasano, 2018, ESMO Open.

A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer.

H. Doihara, S. Takashima, N. Masuda, 2016, Japanese journal of clinical oncology.

Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry.

M. Monden, N. Masuda, M. Ikeda, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer

H. Iwata, A. Armour, Kenichi Inoue, 2015, International Journal of Clinical Oncology.

Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients

H. Doihara, S. Miyoshi, K. Tsukuda, 2011, Cancer Chemotherapy and Pharmacology.

A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer

H. Iwata, H. Sasano, M. Hiraoka, 2013, Breast Cancer Research and Treatment.

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial

K. Inoue, N. Masuda, S. Morita, 2018, Breast Cancer.

Carboplatin calculated with Chatelut's formula plus etoposide for elderly patients with small-cell lung cancer.

M. Fukuoka, N. Masuda, T. Nitta, 2001, Internal medicine.

Palbociclib in combination with letrozole as first‐line treatment for advanced breast cancer: A Japanese phase II study

H. Iwata, Kenichi Inoue, N. Masuda, 2018, Cancer science.

Male Breast Cancer Originating in an Accessory Mammary Gland in the Axilla: A Case Report

Y. Kodama, N. Masuda, M. Sekimoto, 2012, Case reports in medicine.

Pain outcomes in patients with advanced breast cancer and bone metastases

L. Fallowfield, C. Cleeland, A. Stopeck, 2013, Cancer.

Final Results of a Safety and Efficacy Trial of Preoperative Sequential Chemoradiation Therapy for the Nonsurgical Treatment of Early Breast Cancer: Japan Clinical Oncology Group Study JCOG0306

H. Iwata, H. Tsuda, H. Mukai, 2013, Oncology.

TWO CASES OF PRIMARY AND METASTATIC SQUAMOUS CELL CARCINOMA OF THE BREAST

N. Masuda, J. Okamura, M. Sekimoto, 1996 .

Breast metastasis from rectal cancer with BRAF V600E mutation: a case report with a review of the literature

K. Mori, N. Masuda, E. Mita, 2019, Clinical Journal of Gastroenterology.

Comparative D etection o f L ymph N ode M icrometastases o f Stage I I C olorectal C ancer b y R everse T ranscriptase Polymerase C hain R eaction a nd I mmunohistochemi stry

M. Monden, N. Masuda, M. Ikeda, 2002 .

A CASE OF BREAST HEMANGIOMA AND IT'S CHARACTERISTIC IMAGING FINDINGS

N. Masuda, Kazuyoshi Yamamoto, H. Furukawa, 2003 .

Uncertainty of cosmetic evaluation after accelerated partial breast irradiation: interim analysis of a Japanese prospective multi-institutional feasibility study

T. Nose, J. Itami, Kazutaka Nakashima, 2017, Japanese Journal of Radiology.

A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using interstitial brachytherapy: clinical results with a median follow-up of 26 months

T. Nose, J. Itami, Kazutaka Nakashima, 2016, Breast Cancer.

An Icteric Type Hepatocellular Carcinoma with No Detectable Tumor in the Liver: Report of a Case

N. Masuda, T. Tsujinaka, M. Takeda, 2006, Surgery Today.

Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis

H. Iwata, N. Kondo, N. Masuda, 2014, Breast Cancer Research and Treatment.

Comparative genomic hybridization defines frequent loss on 16p in human anaplastic thyroid carcinoma.

M. Monden, Y. Tamaki, N. Masuda, 1999, International journal of oncology.

Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer

K. Yonemori, N. Masuda, M. Tahara, 2022, Cancer medicine.

Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.

H. Rugo, M. Goetz, J. Huober, 2021, The oncologist.

LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC

S. Loi, D. Cescon, V. Karantza, 2021, Annals of Oncology.

Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer

S. Loi, D. Cescon, V. Karantza, 2021 .

Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR + , HER2- metastatic breast cancer

S. Loi, A. DeMichele, S. Loibl, 2016 .

Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project

Y. Kamatani, Yusuke Nakamura, K. Matsuda, 2017, Journal of epidemiology.

The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.

E. Fukuma, N. Masuda, S. Ohno, 2013, Japanese journal of clinical oncology.

A multicenter phase II trial of neoadjuvant letrozole plus low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer (JBCRG‐07): therapeutic efficacy and clinical implications of circulating endothelial cells

H. Tsuda, F. Akiyama, M. Kurosumi, 2018, Cancer medicine.

Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).

H. Iwata, T. Mukohara, K. Yonemori, 2022, Journal of Clinical Oncology.

Unmet Information Needs and Quality of Life in Young Breast Cancer Survivors in Japan

Norikazu Masuda, Eriko Tokunaga, T. Shien, 2015, Cancer nursing.

Clinical significance of the 21‐gene signature (Oncotype DX) in hormone receptor‐positive early stage primary breast cancer in the Japanese population

T. Yamanaka, H. Iwata, N. Masuda, 2010, Cancer.

Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis

H. Iwata, N. Kondo, N. Masuda, 2014, Breast Cancer Research and Treatment.

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)

E. Tokunaga, H. Iwata, Kenichi Inoue, 2021, Cancers.

Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study

H. Iwata, H. Mukai, N. Masuda, 2013, Breast Cancer.

A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study)

F. Akiyama, M. Kurosumi, N. Masuda, 2013, International Journal of Clinical Oncology.

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

C. Petropoulos, H. Iwata, N. Masuda, 2010, BMC Cancer.

Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study

H. Iwata, C. Shimizu, H. Mukai, 2010, Breast Cancer Research and Treatment.

Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)

N. Masuda, N. Kittaka, S. Ohtani, 2021, BMC cancer.

Phase II Trial in Japan of Sequential Administration of Weekly Paclitaxel Followed by FEC as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer [KBCSG0206 Trial: Kinki Breast Cancer Study Group (KBCSG)]

T. Taguchi, S. Noguchi, N. Masuda, 2010, Oncology.

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy

H. Iwata, M. Sugimoto, H. Sasano, 2016, BMC Cancer.

Evaluation of ALDH1 expression in ipsilateral breast cancer recurrence

T. Shien, M. Ishitobi, T. Taguchi, 2016, Oncology letters.

Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)

C. Shimizu, M. Sugimoto, H. Sasano, 2014, Breast Cancer Research and Treatment.

Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients.

K. Mimori, H. Ishii, M. Mori, 2011, International journal of oncology.

Title Clinical significance of the expression of autophagy-associated marker , beclin 1 , in breast cancer patients who

H. Iwata, M. Sugimoto, H. Sasano, 2019 .

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

H. Sasano, N. Masuda, S. Morita, 2018, Cancer medicine.

Postoperative Complications and Mortality Following Elective Surgery for Colorectal Cancer

H. Imamura, N. Masuda, H. Furukawa, 2002 .

Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802).

T. Tabei, S. Takashima, N. Masuda, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Objective Assessment of Dermatitis Following Post-operative Radiotherapy in Patients with Breast Cancer Treated with Breast-conserving Treatment

H. Yamazaki, E. Tanaka, T. Nishimura, 2010, Strahlentherapie und Onkologie.

Longitudinal practical measurement of skin color and moisture during and after breast-conserving therapy: influence of neoadjuvant systemic therapy

H. Yamazaki, N. Masuda, K. Kuriyama, 2009, Japanese Journal of Radiology.

Widespread subdural metastasis from breast cancer progressing rapidly with cerebral herniation: A case report.

K. Mori, Y. Kodama, N. Masuda, 2017, Molecular and clinical oncology.

Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer

T. Yamanaka, H. Iwata, H. Sasano, 2013, International Journal of Clinical Oncology.

Factors Associated with Phlebitis and Venous Pain due to Intravenous Injection of Epirubicin Hydrochloride

N. Masuda, K. Matsuyama, M. Nishikata, 2006 .

A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy

Kenichi Inoue, N. Masuda, M. Kuranami, 2012, Supportive Care in Cancer.

Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.

H. Iwata, H. Tsuda, F. Akiyama, 2011, Japanese journal of clinical oncology.

P4-13-01: Pain Severity and Analgesic Use Associated with Skeletal-Related Events in Patients with Advanced Breast Cancer and Bone Metastases.

L. Fallowfield, C. Cleeland, D. Patrick, 2011 .

Local recurrence risk after previous salvage mastectomy.

T. Shien, M. Ishitobi, T. Taguchi, 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma

H. Iwata, H. Tsuda, F. Akiyama, 2005, Breast cancer.

Role of percutaneous transhepatic biliary drainage in patients with obstructive jaundice caused by local recurrence of gastric cancer.

N. Masuda, T. Tsujinaka, S. Nakamori, 2008, Hepato-gastroenterology.

Results of a phase I/II trial of amrubicin (AMR) in combination with cisplatin (CDDP) as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC).

Y. Ichinose, M. Fukuoka, N. Masuda, 2010 .

Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study

F. Hara, T. Shien, E. Tokunaga, 2021, Breast Cancer.

Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.

H. Iwata, T. Kinoshita, H. Mukai, 2021, The Lancet. Oncology.

Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy

N. Taira, H. Iwata, H. Sasano, 2023, Breast Cancer Research and Treatment.

Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer.

H. Iwata, H. Sasano, N. Masuda, 2012, Breast.

A randomized trial comparing imipenem/cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer.

M. Fukuoka, N. Masuda, M. Takada, 1991, Japanese journal of clinical oncology.

Palbociclib as an early-line treatment for Japanese patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: a review of clinical trial and real-world data

N. Kosaka, H. Iwata, N. Masuda, 2021, International Journal of Clinical Oncology.

Abstract PD1-03: A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial

T. Mukohara, N. Masuda, T. Takano, 2020 .

Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2‒) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies.

H. Rugo, S. Verma, R. Finn, 2018 .

Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database

N. Masuda, M. Kawai, M. Takada, 2022, Breast Cancer Research and Treatment.

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

H. Sasano, N. Masuda, S. Morita, 2019, Cancer medicine.

Probiotic Beverage with Soy Isoflavone Consumption for Breast Cancer Prevention: A Case-control Study

Y. Ohashi, N. Masuda, M. Toi, 2013, Current nutrition and food science.

The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.

Y. Ohashi, K. Suemasu, N. Masuda, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC)

Y. Miyoshi, T. Taguchi, S. Noguchi, 2018, Cancer Chemotherapy and Pharmacology.

95OEfficacy and safety of palbociclib plus endocrine therapy in women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the Asia-Pacific region: Data from PALOMA-2 and -3

H. Mukai, Y. Im, Kenichi Inoue, 2017 .

5167 POSTER A Multicenter Randomized Phase II Study of KRN125 (Pegfilgrastim) to Determine the Optimal Dosage in Japanese Breast Cancer Patients Receiving TAC Treatment

N. Masuda, Y. Tokuda, K. Tamura, 2011 .

Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel

J. Baselga, S. Swain, N. Masuda, 2013, Anti-cancer drugs.

Olaparib efficacy in patients with germline BRCA‐mutated, HER2‐negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial

M. Robson, Bing-he Xu, N. Tung, 2023, International journal of cancer.

Abstract P5-02-42: Soluble CD163 may be a predictive biomarker of the efficacy of nivolumab plus chemotherapy in patients with HER2-negative metastatic breast cancer (WJOG9917BTR)

T. Mukohara, N. Masuda, M. Yamashita, 2023, Cancer Research.

Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur–uracil with CMF (N·SAS-BC 01 trial and CUBC trial)

A. Shimomura, H. Tsuda, F. Akiyama, 2020, Breast Cancer Research and Treatment.

Evaluation of Suspicious Nipple Discharge by Magnetic Resonance Mammography Based on Breast Imaging Reporting and Data System Magnetic Resonance Imaging Descriptors

Hironobu Nakamura, N. Masuda, K. Kuriyama, 2009, Journal of computer assisted tomography.

Stratifying the outcome after neoadjuvant treatment using pathological response classification by the Japanese Breast Cancer Society

C. Shimizu, Takeshi Yamaguchi, H. Mukai, 2015, Breast Cancer.

A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017.

T. Shien, H. Iwata, T. Kinoshita, 2012, Japanese journal of clinical oncology.

Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study.

H. Iwata, N. Masuda, Ling Gao, 2016, Japanese journal of clinical oncology.

Phase II Study of S-1 in Combination with Trastuzumab for HER 2-positive Metastatic Breast Cancer

J. Sakamoto, Y. Miyoshi, T. Taguchi, 2014 .

Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC).

T. Ohmura, H. Mukai, Y. Ohashi, 2010, Japanese journal of clinical oncology.

A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using interstitial brachytherapy: treatment planning and quality assurance

T. Nose, J. Itami, Kazutaka Nakashima, 2015, Radiation oncology.

Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355

H. Iwata, K. Tsugawa, N. Masuda, 2023, Cancer medicine.

HDR-brachytherapy for accelerated partial breast irradiation: Long-term experience from a Japanese institution

T. Nose, H. Yamazaki, E. Tanaka, 2023, Journal of contemporary brachytherapy.

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.

M. Buyse, M. Gnant, H. Iwata, 2023, European journal of cancer.

Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204.

F. Hara, H. Iwata, T. Kinoshita, 2015, Japanese journal of clinical oncology.

[Mohs paste for unresectable local lesion of breast cancer].

N. Masuda, T. Tsujinaka, H. Ogawa, 2008, Gan to kagaku ryoho. Cancer & chemotherapy.

Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer.

H. Iwata, Masayuki Yoshida, H. Mukai, 2010 .

Abstract P5-21-07: Phase II study of eribulin in combination with pertuzumab plus trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer

N. Masuda, S. Morita, M. Toi, 2018 .

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

H. Sasano, N. Masuda, H. Yamashita, 2013, Breast Cancer Research and Treatment.

Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study.

H. Iwata, K. Yonemori, N. Masuda, 2018 .

Case report of a dose-volume histogram analysis of rib fracture after accelerated partial breast irradiation: interim analysis of a Japanese prospective multi-institutional feasibility study

T. Nose, J. Itami, Kazutaka Nakashima, 2018, Journal of contemporary brachytherapy.

Phase II trial of neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide (FEC100) followed by weekly paclitaxel and trastuzumab (PH) for HER2 positive breast cancer (Kinki Multidisciplinary Breast Oncology Group; KMBOG-0402).

T. Taguchi, N. Masuda, M. Takeda, 2009 .

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Multicenter phase II study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity for the breast cancer patients (Kinki Multidisciplinary Breast Oncology Group: KMBOG-0605).

M. Ishitobi, N. Masuda, H. Ueno, 2009 .

[Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].

H. Iwata, H. Mukai, J. Horiguchi, 2015, Gan to kagaku ryoho. Cancer & chemotherapy.

251PEfficacy and safety of olaparib combined with eribulin in patients with advanced or metastatic triple negative breast cancer (TNBC) previously treated with anthracyclines and taxanes: The final analysis of a Japanese phase I/II trial

K. Yonemori, N. Masuda, K. Aogi, 2017 .

Abstract PD1-03: Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results of a phase 1/2 trial

H. Iwata, K. Yonemori, Kenichi Inoue, 2019, Poster Discussion Abstracts.

Abstract P1-14-02: Preoperative docetaxel (T) with or without capecitabine (X) following epirubicin, 5-fluorouracil and cyclophosphamide (FEC) in patients with operable breast cancer (OOTR N003): Results of comparative study and predictive marker analysis

H. Iwata, H. Sasano, N. Masuda, 2012 .

Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial

H. Iwata, J. Watanabe, N. Masuda, 2017, Breast Cancer Research and Treatment.

Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)

F. Hara, N. Masuda, Ken-ichi Watanabe, 2018, Breast Cancer.

Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer.

N. Masuda, S. Kudoh, K. Furuse, 2000, Japanese journal of clinical oncology.

Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer

H. Mukai, N. Masuda, M. Uttenreuther-Fischer, 2015, Cancer Chemotherapy and Pharmacology.

MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer

P. Neven, G. Sledge, X. Pivot, 2019, Annals of Oncology.

Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer

T. Ishikawa, J. Chiu, N. Masuda, 2020, Cancer science.

Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer From SOLAR-1

Xiaolei Zhou, H. Rugo, H. Iwata, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II study of primary systemic chemotherapy and trastuzumab for operable HER2 positive breast cancer.

H. Iwata, Y. Fujiwara, H. Tsuda, 2012, Clinical breast cancer.

Abstract PS12-10: Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR+, HER2- metastatic breast cancer: WJOG11418B NEWFLAME trial

H. Iwata, T. Mukohara, N. Masuda, 2021 .

Interleukin 6 is a cause of flu-like symptoms in treatment with a deoxycytidine analogue.

M. Fukuoka, N. Masuda, N. Kurata, 1998, British Journal of Cancer.

T. Shien, H. Doihara, S. Miyoshi, 2016, Breast Cancer Research.

Pharmacokinetics (PK) of Pertuzumab (P) With Trastuzumab (T) and Docetaxel (D) in HER2-Positive First-Line Metastatic Breast Cancer (MBC): Results From the Phase III Trial Cleopatra

J. Baselga, S. Swain, N. Masuda, 2012 .

H. Rugo, R. Finn, N. Masuda, 2020, Breast Cancer Research.

Clinicopathological Factors Related to the Prognosis of Metastatic Breast Cancer Patients after Development of Brain Metastasis

E. Tanaka, N. Masuda, M. Sekimoto, 2015, Breast Care.

1866 First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) +/- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)

D. Miles, D. Cameron, J. Canon, 2015 .

Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis

H. Iwata, M. Robson, Yeon-Hee Park, 2020, Scientific Reports.

MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy

P. Neven, G. Sledge, X. Pivot, 2017 .

Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)

N. Masuda, S. Ozaki, H. Tada, 2023, Breast Cancer Research and Treatment.

Phase II study of a combination therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer as a first-line treatment (WJOG9917B, NEWBEAT trial).

T. Mukohara, N. Masuda, T. Takano, 2018 .

Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy – results from Paloma-3.

M. Dowsett, S. Loi, H. Iwata, 2016 .

Fulvestrant with or without anti‐HER2 therapy in patients in a postmenopausal hormonal state and with ER‐positive HER2‐positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG‐C06)

E. Tokunaga, M. Yamaguchi, N. Masuda, 2023, Cancer medicine.

[Therapeutic effect of rebamipide for oral mucositis associated with FEC therapy for breast cancer].

N. Masuda, M. Mizutani, J. Yamamura, 2014, Gan to kagaku ryoho. Cancer & chemotherapy.

Prognosis after mastectomy versus repeat lumpectomy in patients with ipsilateral breast cancer recurrence: A propensity score analysis.

T. Shien, M. Ishitobi, T. Taguchi, 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival

H. Iwata, H. Tsuda, F. Akiyama, 2008, Breast Cancer Research and Treatment.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy

H. Iwata, M. Sugimoto, H. Sasano, 2016, BMC Cancer.

[Effect of oral dexamethasone given 24 hours previously on docetaxel-induced edema: a retrospective study].

N. Masuda, M. Mizutani, H. Ueno, 2014, Gan to kagaku ryoho. Cancer & chemotherapy.

Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2.

G. Hortobagyi, J. Baselga, H. Rugo, 2013 .

Abstract P1-13-11: Neratinib in the extended adjuvant treatment of patients from Asia with early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial

H. Iwata, Bing-he Xu, J. Chiu, 2018 .